

2021年11月19日(金) 9:00

プログラム  
配信開始!

2022年11月30日まで掲載予定

ESMO (European Society for Medical Oncology) の公式オンラインプログラム

各領域で著名な先生方が、ESMO Congress 2021の注目演題を日本語で解説

日本の実臨床に即した視点で、最新知見をわかりやすく説明

解説スライドはダウンロード可能(PDF形式)

JSMOがん薬物療法専門医の更新資格に必要な10単位を付与

## 閲覧方法

① トップページ (<https://bestofesmo.jp/>) より  
お申し込み・アクセスキー受領



② トップページ (<https://bestofesmo.jp/>) より  
アクセスキーにてログイン



トップページには  
こちらの二次元  
コードからもアク  
セス可能です。



▼ 以下の先生方による、各領域6演題分の解説が、約30~40分でご視聴可能です。▼

### 領域および解説者一覧

肺がん	鈿持 広知 先生 (静岡県立静岡がんセンター呼吸器内科 医長)
乳がん	佐治 重衡 先生 (公立大学法人 福島県立医科大学 医学部 腫瘍内科学講座 主任教授)
消化器がん	室 圭 先生 (愛知県がんセンター 薬物療法 部長/副院長)
泌尿器がん	三浦 裕司 先生 (国家公務員共済組合連合会 虎の門病院臨床腫瘍科 部長)
メラノーマ&皮膚がん	山崎 直也 先生 (国立研究開発法人 国立がん研究センター中央病院皮膚腫瘍科長)

A collaboration between



Operated by



# 解説演題一覧

## 肺がん

解説者：**鈿持 広知** 先生（静岡県立静岡がんセンター呼吸器内科 医長）

演題番号	演題	演者
LBA9	IMpower010: sites of relapse and subsequent therapy from a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in resected stage IB-IIIa NSCLC	Enriqueta Felip
LBA66	Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial	Nicolas Girard
LBA65	First-line nivolumab + ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year update from CheckMate 743	Solange Peters
LBA46	Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: a multinational phase 2 study (ZENITH20-4)	Robin Cornelissen
LBA44	Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study	Hirotsugu Kenmotsu
LBA50	A randomized phase III study comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab in chemotherapy naïve patients with advanced KRAS mutated non-small cell lung cancer: NVALT22	Anne-Marie C. Dingemans

## 乳がん

解説者：**佐治 重衡** 先生（公立大学法人 福島県立医科大学 医学部 腫瘍内科学講座 主任教授）

演題番号	演題	演者
LBA1	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer: results of the randomized, phase 3 study DESTINY-Breast03	Javier Cortés
LBA15	Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic]-trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer	Cristina Saura
LBA16	KEYNOTE-355: final results from a randomized, double-blind, phase 3 study of first-line pembrolizumab + chemotherapy versus placebo + chemotherapy for metastatic triple-negative breast cancer	Hope S. Rugo
LBA17	Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with endocrine therapy ±ribociclib	Gabriel N. Hortobagyi
118O	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a randomised, phase 3 trial of the Gruppo Italiano Mammella	Lucia Del Mastro
LBA14	Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Interim analysis of the randomised, open-label, phase 2 coopERA BC study	Sara A Hurvitz

## 消化器がん

解説者：**室 圭** 先生（愛知県がんセンター 薬物療法 部長/副院長）

演題番号	演題	演者
LBA7	Nivolumab plus chemotherapy or Ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer / esophageal adenocarcinoma : CheckMate 649 study	Yelena Y. Janjigian
1372O	CLDN 18.2-targeted CAR-T cell therapy (CT041) in patients with cancers of the digestive system	Changsong Qi
LBA6	KRYSTAL-1: adagrasib (MRTX849) as monotherapy or in combination with cetuximab in patients with colorectal cancer harboring a KRAS <sup>G12C</sup> mutation	Jared Weiss
LBA20	FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO	Chiara Cremolini
LBA22	Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a multicenter randomised, open-label, phase III trial	Pei-Rong Ding
LBA56	Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer (NEONAX-AIO-PAK-0313) - final results of a multicenter, randomized phase II study trial	Thomas Seufferlein

## 泌尿器がん

解説者：**三浦 裕司** 先生（国家公務員共済組合連合会 虎の門病院臨床腫瘍科 部長）

演題番号	演題	演者
LBA4	Abiraterone acetate plus prednisolone with or without enzalutamide added to androgen deprivation therapy compared to ADT alone for men with high-risk nonmetastatic prostate cancer: primary combined analysis from two comparisons in the STAMPEDE platform protocol	Gerhardt Attard
LBA5	A phase 3 trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): overall survival with abiraterone acetate plus prednisone in PEACE-1	Karim Fizazi
652O	Dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle invasive bladder cancer : results of the GETUG/AFU V05 VESPER phase III trial	Christian Pfister
LBA27	Erdafitinib or erdafitinib plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor alterations: first results from the phase 2 NORSE study	Thomas Powles
LBA28	STAR. a randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (RCC)	Janet Brown
LBA29	Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: a randomized phase II trial (PRISM)	Naveen Vasudev

## メラノーマ&皮膚がん

解説者：**山崎 直也** 先生（国立研究開発法人 国立がん研究センター中央病院皮膚腫瘍科 科長）

演題番号	演題	演者
1037O	MASTERKEY-265: a phase 3, randomized, placebo-controlled study of talimogene laherparepvec plus pembrolizumab for unresectable stage IIIB-IVM1c melanoma	Helen Gogas
1036O	Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIVITY-047	F. Stephen Hodi
1040O	Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma	Jeffrey Weber
1038MO	Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: preliminary results of the GEM1802 phase II clinical trial	Iván Márquez-Rodas
LBA40	SECOMBIT: the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma. A phase II randomized study.	Ascierto PA
LBA3	Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote-716 double-blinded phase 3 trial	Jason J. Luke